研究单位：[1]Janssen Research & Development, LLC[2]Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology Wuhan, China, 430030[3]Union Hospital Tongji Medical College of Huazhong University of Science and Technology[4]The first affiliated hospital of xiamen university Xiamen, China, 361003[5]Henan Cancer Hospital Zhengzhou, China, 450008[6]Nantong Tumor Hospital Nantong, China, 226000[7]Jiangsu Cancer Hospital Nanjing, China, 210009[8]The First Affiliated Hospital of NanChang University Nanchang, China, 330052[9]Anhui Province Hospital Hefei, China, 230001[10]Zhejiang Cancer Hospital Hangzhou, China, 310022[11]Guangdong Provincial People's Hospital Guangzhou, China, 510120[12]Chongqing University Cancer Hospital Chongqing, China, 400030[13]West China Hospital Sichuan University Chengdu, China, 610041[14]Sichuan Cancer Hospital Chengdu, China, 610041[15]Hunan Cancer hospital Changsha, China, 410013[16]The First Bethune Hospital of Jilin University Changchun, China, 130021[17]Peking Union Medical College Hospital Beijing, China, 100730[18]Peking University Third Hospital Beijing, China, 100191[19]Beijing Cancer Hospital Beijing, China, 100142[20]Beijing Shijitan Hospital, Capital Medical University Beijing, China, 100038
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
